JAMA : the journal of the American Medical Association JAMA, 329(1), 39-51. American Medical Association Journal of the American Medical Association Journal of the American Medical Association, 2023, 329 (1), pp.39-51. ⟨10.1001/jama.2022.23257⟩ Jama : Journal of the American Medical Association, 329, 1, pp. 39-51 Higgins, A M, Berry, L R, Lorenzi, E, Murthy, S, McQuilten, Z, Mouncey, P R, Al-Beidh, F, Annane, D, Arabi, Y M, Beane, A, Van Bentum-Puijk, W, Bhimani, Z, Bonten, M J M, Bradbury, C A, Brunkhorst, F M, Burrell, A, Buzgau, A, Buxton, M, Charles, W N, Cove, M, Detry, M A, Estcourt, L J, Fagbodun, E O, Fitzgerald, M, Girard, T D, Goligher, E C, Goossens, H, Haniffa, R, Hills, T, Horvat, C M, Huang, D T, Ichihara, N, Lamontagne, F, Marshall, J C, McAuley, D F, McGlothlin, A, McGuinness, S P, McVerry, B J, Neal, M D, Nichol, A D, Parke, R L, Parker, J C, Parry-Billings, K, Peters, S E C, Reyes, L F, Rowan, K M, Saito, H, Santos, M S, Saunders, C T & Serpa-Neto, A 2023, ' Long-term (180-day) outcomes in critically ill patients with COVID-19 in the REMAP-CAP randomized clinical trial ', JAMA, vol. 329, no. 1, pp. 39-51 . https://doi.org/10.1001/jama.2022.23257 Bradbury, C A & Higgins, A M 2023, ' Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial ', JAMA-Journal of the American Medical Association, vol. 329, no. 1, pp. 39-51 . https://doi.org/10.1001/jama.2022.23257 Jama : Journal of the American Medical Association, 329, 39-51 JAMA
Dipòsit Digital de la UB Universidad de Barcelona Rosas, I O, Bräu, N, Waters, M, Go, R C, Malhotra, A, Hunter, B D, Bhagani, S, Skiest, D, Savic, S, Douglas, I S, Garcia-Diaz, J, Aziz, M S, Cooper, N, Youngstein, T, Sorbo, L D, De La Zerda, D J, Ustianowski, A, Gracian, A C, Blyth, K G, Carratalà, J, François, B, Benfield, T, Haslem, D, Bonfanti, P, van der Leest, C H, Rohatgi, N, Wiese, L, Luyt, C E, Bauer, R N, Cai, F, Lee, I T, Matharu, B, Metcalf, L, Wildum, S, Graham, E, Tsai, L & Bao, M 2022, ' Tocilizumab in patients hospitalised with COVID-19 pneumonia : Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA) ', EClinicalMedicine, vol. 47, 101409 . https://doi.org/10.1016/j.eclinm.2022.101409
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau instname Amele, S, Peters, L, Rodger, A, Lundgren, J, Rockstroh, J, Matulionyte, R, Leen, C, Jabłonowska, E, Østergaard, L, Bhagani, S, Sarcletti, M, Clarke, A, Falconer, K, Wandeler, G, Domingo, P, Maltez, F, Zaccarelli, M, Chkhartisvili, N, Szlavik, J, Stephan, C, Fonquernie, L, Aho, I & Mocroft, A 2021, ' Effectiveness and Safety of Interferon-Free Direct-Acting Antiviral Hepatitis C Virus Therapy in HIV/Hepatitis C Virus Coinfected Individuals: Results From a Pan-European Study ', J A I D S, vol. 86, no. 2, pp. 248-257 . https://doi.org/10.1097/QAI.0000000000002541